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The authors' enthusiasm for their subject
comes through in the quality of the writing,
and their book will become part of the re-
quired reading for anyone who wishes to take
a serious interest in neutron therapy.
D. GREENE
R. S. POINTON
Cancer Treatment. Ed. C. M. HASKELL
(1980) London: W. B. Saunders & Co.
1133 pp. £27.75.
Cancer Treatment was written as a succinct
"state of the art" book for physicians who
are responsible for the overall care ofpatients
with cancer. The multidisciplinary nature of
modern therapy is emphasised by Charles
Haskell and his colleagues from Los Angeles.
Part 1 of the book deals with the disciplines
relevant to cancer therapy, including surgery,
radiation therapy, chemotherapy, and im-
munotherapy. The disease-orientated chap-
ters which follow in Part II discuss the
contemporary role of each of the oncologic
specialities in cancer treatment. Part III deals
with selective complications of cancer and
its treatment. The contributors are to be
congratulated on producing reviews which are
clear, easily read, comprehensive and un-
biased. The limitations ofcertainexperimental
therapies are clearly stated. It was dis-
appointing, however, that less than 1 page
was devoted to discussion of the role of adju-
vant chemotherapy in breast cancer. There is
good practical advice on the management of
bone marrow failure, malignant pleural
effusions, superior vena caval obstruction,
para-neoplastic syndromes, pain, rehabilita-
tion, and last but not least psychosocial
problems.
This book succeeds in its aim and is the
best of the recent publications on clinical
oncology. It can be strongly recommended to
all interested in the management of patients
with cancer.
J. H. SCARFFE
Preleukemic Disorders. L. KASS (1980)
Springfield: Charles C. Thomas. 189 pp.
Price $21.75.
The purist will define the term 'preleukae-
mia" as the haematological syndrome which
precedes overt leukaemia, but which is not,
at the time, diagnostic of it. For many years,
haematologists have been aware that abnor-
malities such as unexplained red-cell macro-
cytosis, cytopenias, monocytosis, morpho-
logical abnormalities ofmonocytes and granu-
locytes, often accompanied by evidence of
disordered maturation of one or all cell lines
in the marrow, may be prodromas of myelo-
blastic leukaemia or its morphological vari-
ants. Some, though by no means all patients
with these abnormalities will eventually
develop leukaemia, and some authorities have
criticised the term as being valid only as a
retrospective diagnosis. The label has now,
however, been used to cover a wider spectrum
ofblood and marrow pictures which, together,
are frequently referred to as oligoblastic or
'.smouldering" leukaemia. This is logical
because they merge imperceptibly into the
less specific features of the original pre-
leukaemic syndrome, the main difference
being that they show a definite increase in
marrow blasts. In a sense, they might be
regarded as differing from acute leukaemia
quantitatively rather than qualitatively. After
enumerating the blood and marrow findings
of the non-specific pre-leukaemia syndrome,
the present volume reviews in detail the 3
major morphological variants of oligoblastic
leukaemia: "primary acquired panmyelo-
pathy with myeloblastosis" (also known in
the European literature as "refractory
anaemia with excess of blasts") erythro-
leukaemia, and subacute myelomonocytic
leukaemia. As well as a description of the
distinctive morphological features, as seen
by electron and light microscopy, Dr Kass
discusses the cytochemical, metabolic, cyto-
genetic and possible pathophysiological abnor-
malities which characterise each type. Al-
though some of the material has appeared
in the author's earlier book on refractory
anaemias, the chapter on erythroleukaemia
is excellent, and includes a topical discussion
ofthe virus-induced disease seen in mice.
The difficulty is in knowing whether these
morphological entities are also clinical entities
or part of a continuous spectrum of myelo-
dysplasia which results from leukaemic
transformation ofthe haemopoietic stem cell;
the precise picture which results may depend
as much on micro-environmental influences
as on the intrinsic behaviour ofthe leukaemic
cell line; in this context, a parallel might be
drawn with the chronic myeloproliferative
disorders.